Amit Choudhury

Amit Choudhury

Company: Momenta Pharmaceuticals

Job title: Principal Scientist: M267 CD38 SIFbody Program Co-Lead

Bio:

Cell & molecular biologist with 15+ years of post-PhD discovery & translational research experience in therapeutic areas of hematology (myeloma, lymphoma), oncology, autoimmune diseases in academia & pharma environments. Initiated mechanism of actionbased biomarker development efforts to predict outcome and response to therapy & to better position differentiated products to overcome resistance to current standards of care in hematologic malignancies & autoimmunity. Led non-clinical pharmacology projects evaluating MOA of antibody- & Fc multimer-based therapeutics for autoimmune diseases. Performed & directed key non-clinical pharmacology & NHP toxicology projects that enabled discovery stage molecule transition from preclinical to Phase I & Phase II. 

Seminars:

Live Q&A 1:00 pm

Using this opportunity to ask your expert speakers those burning questions.Read more

day: Day Two

Discovery of a Potential Best-in-Class Anti-CD38 Therapeutic Utilizing Fc Multimerization 12:30 pm

Momenta’s proprietary SIFbody technology offers a highly differentiated product scaffold; delivering optimal Fc effector function for effective cell depletion with the potential to induce long-term disease remission Anti-CD38 SIFbody offers the potential to enhance immune cell and complement mediated cytotoxicity against disease causing plasma cells and tumor cells as compared to therapeutic anti-CD38 mAbs In…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.